Annual costs savings of insulin of up to 25%
and plastic waste reduction of up to 50% with Medtronic Extended
infusion set
DUBLIN, Nov. 15,
2022 /PRNewswire/ -- Medtronic plc (NYSE:MDT), a
global leader in healthcare technology, today announced the U.S.
launch of Medtronic Extended infusion set, the first and only
infusion set labelled for up to 7-day wear. An infusion set is
tubing that delivers insulin from an insulin pump to the body and
typically requires a set change every two to three days.
The Medtronic Extended infusion set uses advanced materials that
help reduce insulin preservative loss and maintain insulin
flow and stability to double the wear time of an infusion set. The
innovative design of the Medtronic Extended infusion set leverages
proprietary technology, including a new tubing connector that
improves physical and chemical stability of insulin, the
reliability of infusion site performance, and reduces the risk of
infusion set occlusion.1 The adhesive patch also has an
adhesive layer that helps extend wear time and provides
comfort and durability for up to 7 days.2 In
addition to the new infusion set, the Medtronic Extended reservoir
is the only infusion set reservoir tested and cleared to help keep
insulin stable and safe to use for up to 7 days.3,4
"When patients first begin using a pump, doctors and other
healthcare providers reinforce the need to change their infusion
set every two to three days to limit the risk of infection and
other safety concerns. For many people, this means scheduling life
around infusion set changes, which may not be at the most
convenient times ― turning around as you are headed out the door
when you suddenly remember to change your infusion set or adding a
few minutes to a tired child's bedtime routine with an infusion set
change," said Dr. Robert Vigersky, Chief Medical Officer,
Medtronic Diabetes. "With the Medtronic Extended infusion set,
these life interruptions are reduced with an innovation that
doubles the wear."
In clinical studies of the Medtronic Extended infusion set,
study participants observed a decrease in the number of times an
infusion set needed to be changed by 50% and the number of infusion
set failures associated with high glucose levels was
lowered.3,4 Study participants using the Medtronic
Extended infusion set commented on the new infusion set being more
comfortable to wear compared to their previous infusion sets and
were happy with the longer wear feature in helping reduce the
overall burden of insulin pump therapy.3,4
"Our goal is to make life easier for individuals living with
diabetes and the Medtronic Extended infusion set helps us deliver
on this with prolonged and more comfortable wear – something
customers have been requesting for many years," said Que Dallara,
EVP & President, Medtronic Diabetes. "We couldn't be more
pleased to launch this innovation during Diabetes Awareness Month
when we take the time to reflect on what more we can do to
alleviate the burden for those living with this chronic condition.
We're pleased to deliver a groundbreaking innovation that will make
a real difference in the overall pump experience given the
overwhelming and well-documented benefits of this therapeutic
option."
Additionally, use of the Medtronic Extended infusion set is
estimated to result in annual costs savings of insulin of up to 25%
due to a reduced number of infusion set and reservoir changes that
result in unrecoverable insulin, as well as plastic waste reduction
of up to 50%.5,6
With the U.S. launch of the Medtronic Extended infusion set,
this innovation is now available exclusively for customers using
MiniMed 600 and 700 series pumps.
The Medtronic Extended infusion set was developed in partnership
with Convatec Infusion Care, the world's largest producer of
infusion sets. To learn more about the Medtronic Extended infusion
set, visit MedtronicDiabetes.com/Extended.
About the Diabetes Business at Medtronic
Medtronic is
working together with the global community to change the way people
manage diabetes. The company aims to transform diabetes care by
expanding access, integrating care and improving outcomes, so
people living with diabetes can enjoy greater freedom and better
health. For more information on Medtronic Diabetes,
visit www.medtronicdiabetes.com and
follow @MDT_Diabetes on Twitter and LinkedIn.
About Medtronic
Bold thinking. Bolder actions. We are
Medtronic. Medtronic plc, headquartered in Dublin, Ireland, is the leading global
healthcare technology company that boldly attacks the most
challenging health problems facing humanity by searching out and
finding solutions. Our Mission — to alleviate pain, restore health,
and extend life — unites a global team of 90,000+ passionate people
across 150 countries. Our technologies and therapies treat 70
health conditions and include cardiac devices, surgical robotics,
insulin pumps, surgical tools, patient monitoring systems, and
more. Powered by our diverse knowledge, insatiable curiosity, and
desire to help all those who need it, we deliver innovative
technologies that transform the lives of two people every second,
every hour, every day. Expect more from us as we empower
insight-driven care, experiences that put people first, and better
outcomes for our world. In everything we do, we are engineering the
extraordinary. For more information on Medtronic (NYSE:MDT), visit
www.Medtronic.com and follow @Medtronic on Twitter and
LinkedIn.
Any forward-looking statements are subject to risks and
uncertainties such as those described in Medtronic's periodic
reports on file with the Securities and Exchange Commission. Actual
results may differ materially from anticipated
results.
(1) Zhang G, et al. Development of the Extended Infusion Set and
Its Mechanism of Action. J Diabetes Sci Technol. 2022 Jul
25:19322968221112120. doi: 10.1177/19322968221112120. Epub ahead of
print. PMID: 35876264.
(2) Zhang G, et al. 986-P - Assessment of adhesive patches for an
extended wear infusion set. 80th ADA International Conference, June
2020.
(3) Brazg R, et al, Diabetes Technol Ther. 2022;
Mar 24. doi:
10.1089/dia.2021.0540.
(4) Ilany J, et al. Abstract 416 - Clinical study of a new extended
wear infusion set design. 13th ATTD International Conference.
February 2020.
(5) Kwa et al, The improved survival rate and cost-effectiveness of
a 7-day continuous subcutaneous insulin infusion set, J Med
Econ. Jan-Dec
2021;24(1):837-845.
(6) Fusselman et al. The Extended Wear Infusion Set- A Design for
Plastic Waste Reduction, Journal of Diabetes Science and
Technology, 2021, 15 (3), 397–477.
Contacts:
|
|
|
|
Janet Cho
|
Ryan
Weispfenning
|
Global
Communications
|
Investor
Relations
|
+1-818-403-2078
|
+1-763-505-4626
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/medtronic-launches-worlds-first-and-only-infusion-set-for-insulin-pumps-that-doubles-wear-time-up-to-7-days-in-us-301677790.html
SOURCE Medtronic plc